RU2002130192A - METHOD FOR TREATING OR PREVENTING OBESITY - Google Patents

METHOD FOR TREATING OR PREVENTING OBESITY

Info

Publication number
RU2002130192A
RU2002130192A RU2002130192/14A RU2002130192A RU2002130192A RU 2002130192 A RU2002130192 A RU 2002130192A RU 2002130192/14 A RU2002130192/14 A RU 2002130192/14A RU 2002130192 A RU2002130192 A RU 2002130192A RU 2002130192 A RU2002130192 A RU 2002130192A
Authority
RU
Russia
Prior art keywords
amylin
agonist
administered
amylin agonist
treating
Prior art date
Application number
RU2002130192/14A
Other languages
Russian (ru)
Other versions
RU2314121C2 (en
RU2314121C9 (en
Inventor
Брэдфорд Дж ДАФТ
Орвилль КОЛТЕРМАН
Original Assignee
Амилин Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/870,762 external-priority patent/US7910548B2/en
Application filed by Амилин Фармасьютикалз, Инк. filed Critical Амилин Фармасьютикалз, Инк.
Publication of RU2002130192A publication Critical patent/RU2002130192A/en
Publication of RU2314121C2 publication Critical patent/RU2314121C2/en
Application granted granted Critical
Publication of RU2314121C9 publication Critical patent/RU2314121C9/en

Links

Claims (10)

1. Способ лечения или предупреждения ожирения у человека, включающий введение указанному субъекту эффективного количества амилина или агониста амилина.1. A method of treating or preventing obesity in humans, comprising administering to said subject an effective amount of an amylin or amylin agonist. 2. Способ по п.1, отличающийся тем, что указанный агонист амилина представляет собой аналог агониста амилина.2. The method according to claim 1, characterized in that said amylin agonist is an analog of an amylin agonist. 3. Способ по п.2, отличающийся тем, что указанный аналог агониста амилина представляет собой 25,28,29Pro-h-амилин.3. The method according to claim 2, characterized in that the specified analogue of an amylin agonist is 25,28,29 Pro-h-amylin. 4. Способ по п.1, отличающийся тем, что указанный амилин или агонист амилина вводят подкожно.4. The method according to claim 1, characterized in that said amylin or amylin agonist is administered subcutaneously. 5. Способ по п.4, отличающийся тем, что указанный амилин или агонист амилина вводят от 1 до 4 раз в день.5. The method according to claim 4, characterized in that said amylin or amylin agonist is administered 1 to 4 times a day. 6. Способ по п.5, отличающийся тем, что указанный амилин или агонист амилина вводят в количестве от 30 мкг на дозу до 300 мкг/дозу.6. The method according to claim 5, characterized in that said amylin or amylin agonist is administered in an amount of from 30 μg per dose to 300 μg / dose. 7. Способ по п.6, отличающийся тем, что указанный амилин или агонист амилина вводят три раза в день в количестве примерно 60 мкг на дозу.7. The method according to claim 6, characterized in that the specified amylin or amylin agonist is administered three times a day in an amount of about 60 μg per dose. 8. Способ по п.6, отличающийся тем, что указанный амилин или агонист амилина вводят четыре раза в день в количестве примерно 60 мкг на дозу.8. The method according to claim 6, characterized in that the specified amylin or amylin agonist is administered four times a day in an amount of about 60 μg per dose. 9. Способ по п.7 или п.8, отличающийся тем, что вводят агонист амилина.9. The method according to claim 7 or claim 8, characterized in that the amylin agonist is administered. 10. Способ по п.9, отличающийся тем, что указанный агонист амилина представляет собой 25,28,29Pro-h-амилин.10. The method according to claim 9, characterized in that said amylin agonist is 25,28,29 Pro-h-amylin.
RU2002130192/14A 1997-06-06 2002-11-11 Method for treatment or prophylaxis of obesity RU2314121C9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/870,762 1997-06-06
US08/870,762 US7910548B2 (en) 1997-06-06 1997-06-06 Methods for treating obesity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2000100346/14A Division RU2207871C2 (en) 1997-06-06 1998-06-05 Methods of obesity treatment

Publications (3)

Publication Number Publication Date
RU2002130192A true RU2002130192A (en) 2004-05-20
RU2314121C2 RU2314121C2 (en) 2008-01-10
RU2314121C9 RU2314121C9 (en) 2008-08-10

Family

ID=25356022

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2000100346/14A RU2207871C2 (en) 1997-06-06 1998-06-05 Methods of obesity treatment
RU2002130192/14A RU2314121C9 (en) 1997-06-06 2002-11-11 Method for treatment or prophylaxis of obesity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2000100346/14A RU2207871C2 (en) 1997-06-06 1998-06-05 Methods of obesity treatment

Country Status (10)

Country Link
US (1) US7910548B2 (en)
AU (1) AU7823098A (en)
BR (1) BR9809951A (en)
CZ (1) CZ294983B6 (en)
HU (1) HUP0004271A3 (en)
NO (1) NO324818B1 (en)
NZ (1) NZ501451A (en)
PL (1) PL193236B1 (en)
RU (2) RU2207871C2 (en)
WO (1) WO1998055144A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0996459T3 (en) * 1997-01-07 2006-01-16 Amylin Pharmaceuticals Inc Use of exendins and agonists thereof to reduce food intake
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
JP4353544B2 (en) * 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド Amylin agonist peptide formulation
CA2475173A1 (en) * 2002-01-08 2003-07-17 Amylin Pharmaceuticals, Inc. Use of amylin agonists to modulate triglycerides
WO2005021026A2 (en) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101094689B (en) † 2004-11-01 2013-06-12 安米林药品有限责任公司 Methods of treating obesity and obesity-related diseases and disorders
EA011653B1 (en) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Gip analog and hybrid polypeptides with selectable properties
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
KR20100036326A (en) * 2007-06-29 2010-04-07 론자 아게 Process for the production of pramlintide
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
JP2012523434A (en) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Amylin agonist compounds for estrogen-deficient mammals
RU2552221C2 (en) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Method of treating obesity and accompanying metabolic disorders and medication for treating obesity and accompanying metabolic disorders
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
RU2523558C2 (en) * 2012-08-22 2014-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Россиской Федерации Method of treating and improving life quality of patients suffering from dyspepsia syndrome in combination with obesity
CN107567459B (en) 2015-03-18 2021-09-24 西兰制药公司 Amylin analogs
TWI784968B (en) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 Amylin analogues
CN111050750A (en) 2017-08-24 2020-04-21 诺沃挪第克公司 GLP-1 compositions and uses thereof
EP4106727A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmaceutical formulations
CN116018156A (en) * 2020-04-20 2023-04-25 I2O治疗公司 Use of human amylin analog polypeptides to provide excellent glycemic control in type 1 diabetics

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443619A (en) * 1978-12-26 1984-04-17 Hoffmann-La Roche Inc. Chlorocitric acids
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
IT1219667B (en) * 1988-06-21 1990-05-24 Polifarma Spa USE OF URIDINE IN THE PHARMACOLOGICAL TREATMENT OF DISORDERS DUE TO ALTERATED DOPAMINERGIC BALANCE
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
DE69022501T2 (en) * 1989-07-10 1996-02-01 Amylin Pharmaceuticals Inc Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related diseases.
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
WO1991016917A1 (en) * 1990-05-02 1991-11-14 The Upjohn Company Method of treating gastric ulcers and obesity
SE466130B (en) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab GEL PHOTOGRAPHY LIQUID DIET FIBER COMPOSITION
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (en) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
AU669110B2 (en) 1991-05-24 1996-05-30 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
ES2101866T3 (en) * 1991-08-26 1997-07-16 Upjohn Co LIQUID FOOD PRODUCT CONTAINING 3-GUANIDINOPROPIONIC ACID.
DK0567626T3 (en) 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin Agonist Peptides and Their Use
AU656462B2 (en) * 1992-01-21 1995-02-02 Abbott Laboratories 4"-deoxyerythromycin derivatives
US5376638A (en) 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
AU669636B2 (en) * 1993-05-12 1996-06-13 University Of Cincinnati, The Amylin antagonists and agonists
SK31496A3 (en) * 1993-09-07 1998-06-03 Amylin Pharmaceuticals Inc Use of amylin, amylin agonists and amylin antagonists for regulating gastrointestinal motility
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
DK0756602T3 (en) * 1994-04-14 2000-01-31 Glaxo Wellcome Inc CCK or gastrin modulating 5-heterocyclo-1,5-benzodiazepines
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
TW448046B (en) * 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5646040A (en) * 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
DK0996459T3 (en) * 1997-01-07 2006-01-16 Amylin Pharmaceuticals Inc Use of exendins and agonists thereof to reduce food intake
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition

Similar Documents

Publication Publication Date Title
RU2002130192A (en) METHOD FOR TREATING OR PREVENTING OBESITY
RU2000100346A (en) METHODS FOR TREATING OBESITY
IT8522574A0 (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR TREATING THE HUMAN BODY WITH IT.
FI946173A0 (en) A method for improving the efficacy of drug delivery using modified saponins
BR9606607A (en) Compound method of improving the transport of a drug or other active method of making a drug compound using method of treating a disease and method of preparing a drug
DE3889536D1 (en) TREATING CANCER WITH SOMATOSTATIN AND WITH ANALOGS OF IT.
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
EP0604433A4 (en) Composition and method for disease treatment.
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
RU93054017A (en) METHOD FOR TREATING OSTEOPOROSIS, COMPOSITION FOR TREATING OSTEOPOROSIS, APPLICATION OF ACTIVE PHOSPHONATE AND ESTROGENIC HORMONE FOR TREATING OSTEOPOROSIS
CA2072624A1 (en) Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
MY124210A (en) Use of l-deprenyl for retarding age dependent deterioration in mammals
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
CA2101275A1 (en) Methods for the treatment of osteoporosis
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
EP0658115A4 (en) Peptide medicaments for treating disease.
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
GEP19970992B (en) Implant for Parenteral Introducing with Controlled Speed
EP0744176A3 (en) Methods for inhibiting bone loss
DE69327812D1 (en) ARSEN-CONTAINING MEDICINES FOR TREATING THE CHRONIC FATIGUE SYNDROME
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
EP0321287A3 (en) Inhibition of lipogenesis
NO973340D0 (en) Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of obesity
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
UA41881C2 (en) Drug for treating or preventing inflammation and method for treating or preventing inflammation (variants)